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ABSTRACT  
Therapeutic application of the bone marrow derived stem cells in 
hindlimb ischemia of diabetic mice. 
 
Juyong Lee  
 
Department of Medicine  
The Graduate School, Yonsei University  
 
(Directed by Professor Namsik Chung)  
 
Diabetes mellitus (DM) is one of the greatest risk factors for the cardiovascular disease. 
Diabetes patients have delayed wound healing and recovery from vascular injury. Coronary and 
peripheral occlusive disease and its complication such as acute myocardial infarction and 
peripheral artery disease have been an important issue among in cardiovascular medicine. The 
purpose of these experiments is to show the mechanism of the delayed recovery from the 
ischemic injury in DM and to reveal the molecular functional assessment of the bone marrow 
derived endothelial progenitor cells (EPCs) and mesenchymal stem cells (MSCs) as well as to 
study their therapeutic application with the murine hindlimb ischemia model.  
Blood flow recovery from the hindlimb ischemia was delayed in the diabetic mice. This study 
showed the possible mechanisms for the delay : decrease vascular endothelial growth factor 
(VEGF)-A level in the diabetic skeletal muscle;  decreased circulating EPCs number in DM; 
decreased the important angiogenic cytokines such as VEGF-A, insulin-like growth factor-1, 
angiopoietin-1 in the diabetic bone marrow derived mononuclear cells (BM-MNC) with RT-
PCR; decreased VEGF-A in diabetic EPCs, and MSCs; reduced multiple angiogenesis related 
cytokines in diabetic BM-MNCs, EPCs and MSCs with Microarray, functional derangements of 
EPCs and MSCs for angiogenesis confirmed by migration, adhesion, tube formation assay. 
Transplantation of EPCs and MSCs cultured from normal BM-MNCs to the diabetic hindlimb 
ischemia showed significantly better recovery compared to the saline injection. The mechanism 
of these favorable effects was proposed of increased capillary density, long engraftment of the 
 vi 
injected stem cells up to 2 weeks in vivo, increased cytokines such as VEGF-A, HIF-1α, FGF-
2, and PlGF in the cell transplanted hindlimb, and partly transdifferentiation to the 
newly forming vascular structures of the injected stem cells documented by co-localization of 
injected cells to vessels. In conclusion, DM induced delayed blood flow recovery after ischemia 
and showed dysfunction of bone marrow derived stem cells such as EPCs and MSCs. Normal 
EPCs or MSCs transplantation in to diabetic hindlimb ischemia showed significant 
improvement in their recovery from ischemia.  
 
------------------------------------------------------------------------------------------------------------------- 
Key words: diabetes mellitus, stem cell, endothelial progenitor cell, mesenchymal stem cell, 
Bone marrow-mononuclear cells, hindlimb ischemia  
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Therapeutic application of the bone marrow derived stem cells in hindlimb 
ischemia of diabetic mice. 
 
Juyong Lee  
 
Department of Medicine  
The Graduate School, Yonsei University  
 
(Directed by Professor Namsik Chung)  
 
 
I. INTRODUCTION  
Diabetes mellitus (DM) comprises a heterogeneous group of disorders characterized by high 
blood glucose levels. DM is one of the most important diseases in national health system in US 
in the 21st century because, as prevalence and incidence of DM have been increasing, mortality 
and morbidity from it also are increasing. Accordingly, its economic impact is also considered 
being important. From 1980 through 2003, the number of Americans with diabetes more than 
doubled (from 5.8 million to 13.8 million). In 2003, about 4.9% of the U.S. population reported 
that they had diabetes.  People aged 65 years or older account for almost 40% of the 
population with diabetes 1, 2 
Most of the DM morbidity related its chronic complications. Disability is the major social issue 
resulted from DM. The major cause of DM related disabilities is peripheral artery occlusive 
disease (PAOD), or amputation. Center for disease control (CDC) data revealed that PAOD, 
foot ulcer, and neuropathy are costly and disabling conditions in diabetic patients that can lead 
to lower extremity amputation2. Among the three, PAD which resulted from artery occlusion or 
stenosis is the most troublesome cause of amputation. Peripheral artery occlusive disease 
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(PAOD) is identified clinically by intermittent claudication and/or absence of peripheral pulses 
in the lower legs and feet, representing decreased arterial perfusion of the extremity. Most of the 
lower extremity amputation level was below knee (1.6/1,000), and the highest was toe 
amputation(2.6 per 1000)3.  That means severe small vessel disease of lower extremity has no 
optimal therapeutic option and finally lead to make the patients extremity amputed. 
Among all the PAOD, critical limb ischemia refers to a condition characterized by chronic 
ischemic at-rest pain, ulcers, or gangrene in one or both legs attributable to objectively proven 
arterial occlusive disease. Critical limb ischemia implies chronicity and is to be distinguished 
from acute limb ischemia which is usually caused from embolic occlusion. Most of the diabetic 
PAOD is chronic arterial occlusive disease which means, in the end, most of the peripheral 
below knee arteries are diffusely occluded and there are not many options to survive the leg 
muscles but amputation to survive the patients themselves. 
Although the strengths of surgical revascularization in severe peripheral arterial disease are well 
recognized, not all needed patients can have appropriate revascularization. In a large proportion 
of these patients, the anatomic extent and the distribution of arterial occlusive disease make the 
patients unsuitable for operative or percutaneous revascularization4, 5.  In general, by-pass 
grafting and percutaneous interventions are reserved only for patients with critical limb-
threatening ischemia caused from discrete, proximal artery disease, such as femoral or, at the 
most, popliteal artery stenosis6. However, diffuse severe infra-popliteal small arterial stenosis 
has no good option to improve symptoms and to survive muscle. Thus, the disease frequently 
follows an inexorable downhill course. Therefore, beyond the generally used surgical-medical 
treatment modalities, novel therapeutics is necessary to treat these severe terminal complicated 
diabetic peripheral artery disease patients. That is the new vessel formation which is 
neovascularization. 
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Generally speaking, the new vessel formation has three way including angiogenesis which 
means the sprouting of new capillaries from existing vascular structures, vasculogenesis which 
means the in situ formation of new blood vessels from circulating bone marrow-derived 
endothelial progenitor cells or other stem cells that differentiate into endothelial cells, and 
arteriogenesis which refers to an increase in the caliber of pre-existing arteriolar collateral 
connections by recruitment of perivascular cells and expansion and remodeling of the 
extracelluar matrix7. The early age of studies of therapeutic revascularization used recombinant 
protein or the gene that codes for angiogenic growth.  
The first case report of therapeutic angiogenesis in 1996 was VEGF gene transfer in a patient 
with critical limb ischemiab8, after then, there have been numerous clinical studies of different 
angiogenic agents in PAOD. There is no doubt that these protein or gene based therapeutic trial 
has opened the new era of treatment of critical limb ischemia. However, having discouraged the 
wonderful expectation of protein or gene therapy, they have not been totally applied to the 
clinics due to some not-solved major limitations such as inconsistent and inconclusive results of 
clinical data and some unexpected side effects including unwanted neovascularization, tumor 
growth, hemorrhage from fragile new vessels, and even an adverse effect on atherosclerotic 
plaques8-10. In addition to these arguing points, protein or gene base therapy has still much to 
learn about the optimum treatment modality, dosing frequency and route of administration. For 
this reason, there must be new notion to overcome these limitations. 
As an alternative, what it comes down to is new techniques, stem cell based therapy.  In this 
regard, these days, according to the development of stem cell handling techniques, critical limb 
ischemia have been adapted various kinds of stem cells in its studies which not only help 
angiogenesis with angiogenic cytokines but also may be transformed to endothelial cells, 
vascular smooth muscle cells, as well as skeletal muscle cells in the ischemic area.  
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Among the stem cells in body, bone marrow-derived stem cells such as endothelial progenitor 
cells (EPCs) from bone marrow or peripheral blood,11-13 are one of the best candidates. The adult 
bone marrow contains hematopoietic (1–2%) and stromal (<0.05%) stem/progenitor cells. Bone 
marrow stromal stem cells include adult mesenchymal stem cells (MSC) and multipotent adult 
progenitor cells, which are capable of multilineage differentiation14. The mononuclear fraction 
of bone marrow consist of various subpopulations which have the potential to participate in the 
repair and regeneration of diseased myocardium in vivo through transdifferentiation into 
cardiomyocytes and initiate neovascularization by expressing various angiogenic cytokines 15. 
Among the cells from bone marrow mononuclear fraction, MSCs, EPCs are well known for the 
regenerative therapy. MSCs remain undifferentiated with stable phenotype and may be 
reprogrammed to transdifferentiate into cardiomyocytes and increase the recovery capacity after 
hindlimb ischemia16, 17.  EPCs have the capacity to initiate neovascularization to alleviate 
myocardial and hindlimb ischemia12, 18. Hence, the heterogeneous mononuclear fraction of the 
bone marrow is the most promising stem cell population for cellular regenerative therapy.  
As the morbidity and mortality of diabetes mellitus increase, it became an important subgroup 
that may have definite benefit from therapeutic angiogenesis and cell therapy. However, So far, 
there have been few data about stem cell treatment in the diabetic hind limb ischemia.  
What make DM more interesting is that it has distinctive pathophysiology and therapeutic 
response to ischemia and stem cell therapy compared to non-diabetic patients. So far there have 
been some data that showed the differences. The physiologic mechanisms leading to collateral 
vessel formation to ischemia is insufficient in patients with diabetes19-21. Especially Diabetes 
and raised levels of cholesterol and lipoprotein (a) are associated with a reduced angiogenic 
response22, 23. In patients with diabetic retinopathy triggering neovascularization plays an 
important role in new vessel formation around the optic disc and in sight-threatening macular 
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edema24. Therefore, it is important that we should focus on the diabetic ischemic limb disease 
with different eyes. Moreover, recently, researchers have been thinking the reason why diabetic 
patients have different response to therapeutic neovascularization. They are pursuing that stem 
cells of diabetic patients might have some serious dysfunction, and it has been documented from 
recent researches. It has been shown that patients at risk for coronary artery disease have 
decreased numbers of circulating EPCs with impaired activity25. Some study also suggest that 
vasculogenesis may be impaired in animal models of diabetes mellitus26. Others revealed that 
human endothelial progenitor cells from Type II diabetics exhibit impaired proliferation, 
adhesion, and incorporation into vascular structures 9. The others said that adverse metabolic 
stress factors in type 1 diabetes are associated with reduced EPC numbers and angiogenicity27. 
Not only EPC, but also BM-MNC showed a impairment in ischemia-induced neovascularization 
in diabetes28. Therefore, it is definite that diabetes has major pathophysiology different form 
other disease in the aspect of neovascularization and stem cell therapy. So far, there has been no 
data showed dysfunction of MSCs in DM. 
Therefore, the hypothesis and aims of this research are followed. We hypothesized that there 
might be a do novo defect in the hind limb such as decreased cytokines in the diabetic skeletal 
muscle. Bone marrow, which may act supporters via mobilization of stem cells to the tissue, 
also may has dysfunction. Firstly, we focused on the mechanisms of impaired 
neovascularization in the diabetic hind limb in the various ways. We tried to figure out the 
differences between diabetic and non-diabetic BM-MNC, EPCs, and MSCs in their molecular 
characteristics especially in terms of the content of the important cytokines. Secondly, we 
studied functional differences between diabetic and non-diabetic stem cells. With the results of 
these data, we hypothesized that diabetic stem cells need, so called, normal non-diabetic stem 
cells in the ischemic condition. Therefore, thirdly, we studies if normal, not diabetic, bone 
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marrow-derived stem cells such as EPCs or MSCs have the therapeutic effect in the hindlimb 
ischemia. We also studied the difference in the therapeutic effect of EPCs and MSCs and the 
mechanisms incurring the therapeutic effects in the various ways.  
 
II. MATERIALS AND METHODS  
 
1. Induction of Diabetes Mellitus  
C57Bl/6 male mice (8 weeks old, The Jackson Laboratory, USA) weighing 20 to 25grams were 
used. Mouse was fed standard laboratory murine chow and water ad libitum and housed 3 
diabetic mice and 5 non-diabetic mice in a cage.  
To induce moderate diabetes, C57Bl/6 mice were intraperitoneally injected 40 mg/kg 
of streptozotocin (STZ; Sigma-Aldrich, St. Louis, MO, USA) in 0.9% sterile saline daily for 5 
consecutive days. In the majority of treated mice (around 85%) this procedure creates a 
moderate diabetic condition that allows them to survive for up to 4 months after treatment 
without receiving insulin supplementation.  Seven days after the injection, blood glucose levels 
were measured using Accu-Check glucometer (Roche, Indianapolis, IN, USA). If serum glucose 
was more than 200 mg/dl, they were considered as a diabetic mouse. Mice with glucose levels 
less than 200 mg/dl were excluded from further study. Mean glucose levels were 380±50 
mg/dl.  Except for a gradual weight loss, the health of the mice was not overtly affected by the 
treatment throughout the experimental period. All diabetic mice maintained for 3 months after 
streptozotocin injection, after then, they were used for the experiments.  Before using, glucose 
levels were retested again to ensure serum glucose level of greater than 200 mg/dl. In the non-
diabetic groups, mice were injected intraperitoneally with 0.9% sterile saline.  
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2. Cell Culture  
A. Bone Marrow–derived EPC Culture  
Bone marrow–derived mononuclear cells isolated tibia and femur were plated on cell culture 
dishes coated with rat vitronectin at a density of 5×105 /cm2 and cultured in endothelial cell 
basal medium-2 (EBM-2, Clonetics) supplemented with 5% fetal bovine serum (FBS), human 
vascular endothelial growth factor (VEGF)-A, human fibroblast growth factor-2, human 
epidermal growth factor, insulin-like growth factor-1, ascorbic acid, and antibiotics. After 4 
days in culture, non-adherent cells were removed by washing with PBS, new medium was 
applied, and the culture was maintained through 7 days. The cells were used as EPC-rich cell 
population for real time RT-PCR analysis and cell transplantation29, 30.  
B. Bone Marrow-derived MSCs Culture  
Whole bone marrow cells were plated in high-glucose Dulbecco's Modified Eagle Medium 
(DMEM, Cambrex Co. USA) supplemented with 10% FBS and 50units/mL 
penicillin/streptomycin. After 5 to 7 days of incubation in a humidified incubator at 37°C with 
5% CO2, the non-adherent hematopoietic cells were discarded. The adherent MSCs were further 
maintained in a humidified incubator at 37°C with 5% CO2 in the absence of any exogenous 
growth factor or anchoring materials such as fibronectin or collagen. MSCs were kept 
subconfluent and expanded in number over 3 passages by a 1:2 split on a weekly basis. Two 
morphologically different components of plastic adherent MSCs were identified, spindle 
fibroblastoid MSCs and round or satellite-shaped MSCs. Passage 3 cells are used for real time 
RT-PCR and cell transplantation31.  
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3. Mouse Ischemic Hindlimb Surgery and Stem Cell Transplantation  
A. Ischemic Hindlimb Surgery  
Unilateral hindlimb ischemia was created in diabetic or non-diabetic C57Bl/6 mice as 
previously described32. The animals were anesthetized with pentobarbital (160 mg/kg 
intraperitoneally) following which an incision was performed in the skin overlying the middle 
portion of the left hindlimb. After ligation of the proximal end of the femoral artery, the distal 
portion of the saphenous artery was ligated and the artery, as well as all side-branches, was 
dissected free and excised. The skin was closed using a surgical stapler.  
 
B. Transplantation of Ex Vivo Expanded EPCs, MSCs  
The impact of EPCs, MSCs transplantation on therapeutic neovascularization was investigated 
in a murine model of hindlimb ischemia.  Just after operative excision of one femoral artery, 
described above, the diabetic C57BL/6 mice received the 4 points local intramuscular injection 
of MSCs (1×106) or EPCs (1×106) versus saline along the path of dissected femoral artery. Cells 
were labeled with Ac-LDL-DiI solution (0.1-0.3 ul, Biomedical Technologies, Stoughton, MA) 
for the cell tracking after sacrifice on the designated day.  
 
C. Monitoring of Hindlimb Blood Flow  
After anesthesia, hair was removed from both legs using a depilatory cream, following which 
the mice were placed on a heating plate at 37oC for 10 minutes to minimize temperature 
variations. The hindlimb perfusion was measured using a laser Doppler perfusion imager 
(LDPI) system (Lica Inc., North Brunswick, NJ, USA). The LDPI uses a beam from a 2-mW 
helium-neon laser that sequentially scans a 12 X 12 cm tissue surface to a depth of a few 
hundred microns. During the scanning procedure, the moving blood cells shift the frequency of 
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incident light according to the Doppler principle. A photodiode collects the back-scattered light, 
and the original light intensity variations are transformed into voltage variations in the range of 
0 to 10 V. A perfusion output value of 0 V was set to 0% perfusion, whereas 10 V was set to 
100%. When the scanning procedure is terminated and the back-scattered light collected from 
all of the measured sites, a color-coded image representing the microvascular blood flow 
distribution appears on a monitor. The perfusion signal is split into six different intervals, each 
displayed in a separate color. Low or no perfusion is displayed in dark blue, whereas the highest 
perfusion interval is displayed in red. The stored perfusion values behind the color-coded pixels 
are then available for analysis. Consecutive measurements were obtained after scanning the 
same region of interest (leg and foot) with LDPI. Color photographs were recorded and analysis 
performed by calculating the average perfusion of the ischemic and non-ischemic foot. To 
account for variables such as ambient light and temperature, the results are expressed as the 
ratio of perfusion in the left (ischemic) versus right (normal) limb33.  
 
D. Tissue Preparation  
The mice were sacrificed at predetermined arbitrary time points after surgery with an overdose 
of sodium pentobarbital. For the in vivo perfusion capillary staining, 100 ul of Fluorescein 
griffonia simplicifolia lectin I (Vector laboratories, USA) was injected into the heart before 
sacrifice and kept circulating for 20 minutes in the blood.  Whole hind limbs (thigh area) except 
bone were immediately frozen with liquid nitrogen and isopentan-2-methybutan (Sigma-Aldrich, 
St. Louis, MO, USA) and stored at -80oC until use.  The tissue was used for total protein, 
mRNA extraction, and immunohistochemistry.  
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4. Microarray for the angiogenic cytokines 
Total RNA was extracted from tissue or cells with RNA-Stat (Tel-Test INC., Friendswood, TX, 
USA) according to the manufacturer's instructions and purified using the Arraygrade Total RNA 
isolation kit (Superarray) following the manufacturer’s instructions. We quantitated RNA with 
spectrophotometer in 10mM Tris EDTA buffer (PH 8.0). A Oligo GEArray mouse angiogenesis 
series was obtained from Sueprarrray Inc. (Bethesda, MD, USA). This array includes 112 genes 
involved in angiogenesis, including Ephrin Family Members, fibroblast growth factors (FGF), 
Platelet-Derived Growth Factors, Transforming growth factors (TGF) and vascular endothelial 
VEGF families etc. (See www.superarray.com for details). A Total of 3ug RNA was used as a 
template to generate Biotin-16-dUTP-labeled cDNA probes (Roche, 11388908) according to the 
manufacturer’s instructions. The cDNA probes were denatured and hybridized at 60 ºC with the 
Superarray membrane (OMM-024). 
After overnight at 60 ºC, the membrane was washed twice with 2x SSC containing 1% SDS for 
15min, once with 0.1x SSC containing 0.5% SDS for 15min, blocked and exposed with the use 
of a chemiluminescent substrate. To analysis the Superarray membrane, we scanned the X –ray 
film and imported it into Adobe Photoshop program as a TIFF file. The image file was inverted, 
and the spots were digitized with the use of Analysis software (http://www. superarray.com/ 
support_software.php), and normalized by subtraction of the background as the average 
intensity value of 3 spots. The averages of 2 GAPDH or RPL32 spots were used as positive 
controls and set as baseline values with which the single intensity of other spots were compared. 
Using these normalized data, we compared the single intensity from the membranes using the 
GEArray analyzer program. Genes were considered differentially expressed when logarithmic 
gene expression ratios in hybridization were more than 1.4 fold difference in expression level. 
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5. RNA Extraction and quantitative Real Time Reverse Transcriptase–Polymerase Chain 
Reaction (RT-PCR) Analysis  
Total RNA was extracted from tissue or cells with RNA-Stat (Tel-Test INC., Friendswood, TX, 
USA) according to the manufacturer's instructions. First-strand cDNA was generated using the 
Taqman Multiscribe Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA) 
primed with a mix of oligo dT and Random Hexamers. Gene expression was determined by 
Taqman real-time quantitative PCR on the 7300 Sequence Detection System (Applied 
Biosystems, Foster City, CA, USA) using Taqman PCR Master Mix (Applied Biosystems, 
Foster City, CA, USA). Taqman primer/probe sets (Biosearch Technologies, Novato, CA, USA) 
shown in Table 1 were designed using Primer Express Software (Applied Biosystems, Foster 
City, CA, USA). The PCR Conditions were as follows: hold for 2 min at 50C, and 10 min at 
95C followed by 2 steps PCR for 40 cycles of 95oC for 15 seconds and 60C for 60 seconds with 
fluorescence monitoring at the end of each elongation step. Relative mRNA expression of target 
genes was calculated with the comparative CT method. All target sequences were normalized to 
GAPDH in multiplexed reactions performed in duplicate. Differences in CT values were 
calculated for each target mRNA by subtracting the mean value of GAPDH (relative expression 
= 2-DCT). 
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Table 1.  
Oligonucleotide primers used for gene expression analysis by real-time RT-PCR  
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6. Immunohistochemistry  
The histological sections, 6 um thick, prepared from frozen tissue samples of the lower limbs 
were used for immunohistochemical analysis. Identification of endothelial cells was performed 
by immunohistochemical staining for platelet endothelial cell adhesion molecule-1 (PECAM-1 
or CD31) using a rat monoclonal antibody directed against mouse CD31 (Pharmingen, San 
Diego, CA, USA).  Immunofluorescence staining was performed as previously described (14). 
In brief, to prevent nonspecific antibody binding, sections were preincubated for 20 minutes in 
PBS containing 10% horse serum after cold aceton fixation for 10 minutes. Next, sections were 
incubated with the primary antibodies directed against CD31 at appropriate dilutions overnight 
at 4oC. Sections were then rinsed for 15 minutes with PBS, followed by incubation with Cy2 
labeled secondary antibody (Pharmingen, San Diego, CA, USA) for 1 hour at room temperature. 
After a 15-minute wash, Sections were rinsed with PBS.  Negative control slides were prepared 
by substituting pre-immune rat serum for CD31. For the assessment of cell proliferation after 
designated stem cell transplantation, the detection of Ki67 antigen was performed. In brief, after 
cold aceton fixation for 10 minutes, epitope retrieval method was used with DakoCytomation 
target retrieval solution (DakoCytomation, Carpinteria, CA, USA). Then rabbit anti-human 
Ki67 (Novocastra, UK) and Cy3 goat anti-rabbit IgG (Pharmingen, San Diego, CA, USA) were 
used as a primary and secondary antibody, respectively.  
 
7. Stem Cell Function Assay  
A. EPC culture assay  
EPC culture assay was performed as described previously (15). Briefly, mononuclear cells 
isolated from 500 µL of peripheral blood were cultured in EBM-2 (Clonetics, USA) on rat 
vitronectin (Sigma-Aldrich, St. Louis, MO, USA) with 0.1% gelatin-coated 4-well glass 
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chamber slides. After 4 days in culture, cells were coincubated with DiI-acLDL (Biomedical 
Technologies, Stoughton, MA, USA) for 1 hour, followed by FITC-BS-1 lectin (Sigma-Aldrich, 
St. Louis, MO, USA) staining for 2 hours at 40C. The dual-stained cells, considered EPCs, were 
counted in 10 randomly selected high-power fields (x200) under a fluorescent microscope34.  
 
B. EPC Tube formation assay  
Matrigel (Becton Dickinson, San Jose, CA, USA) was coated into 2-well glass chamber and 
incubated in a CO2-free incubator at 37°C for 30 min. The same batch of Matrigel was used for 
all of the experiments. The gels were then overlaid with 2.5 x 105 cells suspended in culture 
medium and incubated at 37°C in an atmosphere of 5% CO2. Gels were examined by using a 
phase-contrast microscope equipped with a digital camera. A second observer measured the 
total length of the tube-like structures (defined as those exceeding 200 µm in length) per each 
image35.  
 
C. EPCs adhesion assay  
Seven day-diabetic and non-diabetic EPCs were washed with PBS and gently detached with 
0.25% trypsin. After centrifugation and resuspension in the EPC media with 5% FBS, identical 
cell numbers (2X104 cells / well) were replated onto vitronectin (Sigma-Aldrich, St. Louis, MO, 
USA) or laminin (Sigma-Aldrich, St. Louis, MO, USA) -coated 96-well plate in 100 ul cell 
solution per well and incubated for 1 hour at 37 °C. Adherent cells were counted by independent 
blinded investigators36.  
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D. EPCs and MSCs migration assay  
The day 4 cultured EPCs and passage 3 MSCs were used for the migration assay. Each assay 
was done separately. After cells were detached mechanically, harvested by centrifugation, 
resuspended in EBM with 3% FBS (without VEGF) for EPCs and in DMEM with 10 % FBS for 
MSCs and counted. Next, 6×104 of EPCs, 8x104 of MSCs were placed in the upper chamber of a 
modified Boyden chamber which was placed in a 24-well culture dish respectively. In the lower 
chambers, the same medias for each cell line but included human recombinant VEGF (100 
ng/mL) (Sigma-Aldrich, St. Louis, MO, USA) were used. After 16 h of incubation at 37oC, the 
lower side of the filter, containing the migrated cells, was washed with PBS and fixed with 2 % 
paraformaldehyde. For quantification, cell nuclei were stained with Diff-Quick stain set (Dade 
Behring Inc., Newark, USA) and counted in three random microscopic fields. Measurement was 
performed in a duplicate manner 37(19).  
 
8. Statistical analysis  
Data were expressed as a mean value ± SE. Statistical comparisons between the groups were 
made with t-test and an analysis of variance test with post hoc analysis. A P value <0.05 was 
considered significant.  
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III. RESULTS  
1. Physiologic data  
Blood pressure did not differ between the 2 groups on the day of surgery. Significant 
differences were observed in body weight, plasma glucose between diabetic and non-diabetic 
mice (Table 2).  
 
 
 
 
Table 2.  Physiologic data  
 
 
 
2. Decreased neovascularization in diabetic hindlimb muscle in the absence of hindlimb 
ischemia surgery 
To evaluate the baseline difference of neovascularization between diabetic and normal mice 
hindlimb without ischemia, we compared capillary density with CD31 immunochemical 
staining. Quantitative analysis of capillary density in ischemic adductor muscle of diabetic and 
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non-diabetic C57BL/6 mice was determined in histological sections harvested 3 months later of 
induction of DM. To confirm the reduction of muscle mass in the diabetic mice, the tendon to 
tendon Gastrocnemius muscle was isolated and weighted. Diabetic muscle showed significantly 
reduced in the muscle size and weight compared to the non-diabetic mice (Figure 1). 
Quantitative analysis of CD 31-positive cells revealed that the capillary density per single 
myofiber was essentially decreased in the diabetic mice (Figure 2) indicative of an impaired 
angiogenic response in these animals.  
 
3. Decreased amount of VEGF-A in the diabetic hindlimb 
To figure out the reason of the decreased capillary density in the baseline statues of DM, we 
measure VEGF-A , the most important cytokines among the angiogenic cytokines, Figure 3 
shows that diabetic hindlimb muscle has the smaller amount of VEFG-A mRNA. This 
suggested the possible mechanism of impaired angiogenesis after hindlimb ischemia in the 
diabetic mouse. 
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Figure 1.  The Gastrocnemius muscle size was significantly reduced in the diabetic mice (b) 
compared to the non-diabetic normal mice (a).  The weight of Gastrocnemius muscle was 
significantly smaller in the diabetic mice compared to the non-diabetic mice (* p<0.03).  
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Figure 2. Baseline capillary density of hindlimb muscle with CD-31 immunofluorescence 
staining. A: Representative picture from diabetic (a) and non-diabetic normal (b) hindlimb. 
Because of the atrophy of single muscle fiber in the diabetic mice, the number of CD-31 
positivity looks higherr in the diabetic muscle with high power field magnification. B: However, 
when counting quantitatively for each myofiber, the number of capillary was significantly less 
in the diabetic hindlimb compared to the normal.  
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Figure 3. Real time RT-PCR of hindlimb for vascular endothelial growth factor-A (VEGF-A) 
revealed that diabetic hindlimb had smaller amount of mRNA for VEGF-A compared to that of 
the normal non-diabetic hindlimb.  
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4. Impairment of angiogenic property of bone marrow-derived mononuclear cells, EPCs, 
and MSCs: qualitative change (Microarray, RT-PCR, and cell biology study) 
Microarray was performed to compare the difference of angiogenic cytokines between diabetic 
and non-diabetic bone marrow-derived mononuclear cells, EPCs, and MSCs. There were a total 
of 12 cytokines among 112 angiogenesis related cytokines that showed more than 1.4 fold 
decreases in the diabetic cells (Table 3). Microarray for EPCs showed a total of 11 cytokines 
reduced in the diabetic EPCs compared to normal EPCs (Table 4).  Only 3 cytokines were 
reduced in the diabetic MSCs compared to normal MSCs with Microarray (Table 5). 
Real time RT-PCR was performed with the bone marrow-derived mononuclear cells (MNC), 
EPCs, MSCs. Diabetic bone marrow derived MNCs showed significantly decrease amount of 
the mRNA for angiopoietin-1, and also showed smaller amount of mRNA for the vascular 
endothelial growth factor(VEGF)-A and insulin-like growth factor (IGF)-1 without significance 
(Figure 4). Diabetic bone marrow derived EPCs and MSCs showed smaller amount of mRNA 
for the VEGF-A compared to non-diabetic stem cells (Figure 5). When it comes to say the 
recovery after injury, bone marrow derived stem cells have an important role in their 
mobilization into the injury sites. However, in the diabetic animals the bone marrow MNC itself 
are deficient of some important angiogenic cytokines. Therefore, these finding also give rise to 
the mechanism of the impaired angiogenicity in the diabetic mice.  
We assessed the EPCs MSCs angiogenic property with several functional studies. We did firstly 
compare the adhesion activity between diabetic EPCs, MSCs and normal cells because adhesion 
to the extracellular matrix is believed to be important during new blood vessel growth 
and recovery after ischemia.  Diabetic EPCs were found to be significantly impaired in their 
ability to adhere to Laminin and Vitronectin compared to normal EPCs (Table 3). A Matrigel 
tubule assay was performed to investigate the ability of EPCs to make vessel like structures. 
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Cultures of EPCs within Matrigel led to the formation of an extensive tubule network in normal 
non-diabetic EPCs. However, diabetic EPCs showed significantly reduced length of the tube 
compare to non-diabetic EPCs (Figure 6). Migration assay of EPCs to VEGF-A revealed 
decreased migration in normal EPCs compared to diabetic EPCs. Migration assay to MSCs to  
VEGF-A showed the same pattern of result (Figure 7).  
 
 
 
Table 3. Angiogenesis related cytokines that showed more than 1.4 fold changes between 
diabetic and non-diabetic normal bone marrow-derived mononuclear cells (BM-MNC) among 
the 112 tested cytokines with Microarray. 
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Table 4. Angiogenesis related cytokines that showed more than 1.4 fold changes between 
diabetic and non-diabetic normal endothelial progenitor cells (EPCs) among the 112 tested 
cytokines with Microarray. 
 
 
 
 
Table 5. Angiogenesis related cytokines that showed more than 1.4 fold changes between 
diabetic and non-diabetic normal mesenchymal stem cells (MSCs) among the 112 tested 
cytokines with Microarray. 
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Table 6. Adhesion assay of endothelial progenitor cells (EPCs) to Laminin and Vitronectin 
revealed that diabetic EPCs showed the decreased adhesion to laminin and vitronectin compared 
to normal non-diabetic EPCs. 
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Figure 4. Real time RT-PCR of bone marrow-derived mononuclear cells (BM-MNCs) for 
vascular endothelial growth factor (VEGF-A), insulin-like growth factor-1 (IGF-1), 
angiopoietin-1 (ANG-1) revealed that diabetic BM-MNCs had smaller amount of mRNA for 
ANG-1 compared to normal cells.  
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Figure 5. Real time RT-PCR of endothelial progenitor cell (EPCs) (A) and mesenchymal stem 
cells (MSCs) for vascular endothelial growth factor-A (VEGF-A) (B) showed that diabetic 
endothelial progenitor cells (BM-EPCs), mesenchymal stem cells (MSCs) had smaller amount 
of mRNA of VEGF-A compared to normal cells.  
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Figure 6. Matrigel tube formation assay for EPC. EPCs were plated within Matrigel to form 
tubule structures. A:  Quantification of EPC tube formation revealed that significantly smaller 
tube length in the diabetic EPCs. B: Non-diabetic normal EPCs made a substantial contribution 
to tubule network (B-a). In contrast, diabetic EPCs showed nearly absent tube formation (B-b).  
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Figure 7. Migration assay showed decreased migration toward VEGF-A in the normal EPCs and 
normal MSCs compared to diabetic EPCs and MSCs respectively.  
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5. Decreased number of peripheral circulating EPCs in the diabetic mice: quantitative 
change 
To further reveal the mechanism of the impaired angiogenic response in the diabetic mice, we 
guessed that the circulating EPCs probably reduced in the non-ischemic diabetic mice. As a 
functional index of baseline circulating EPCs, the EPC culture assay was employed. The 
number of cultured EPCs, confirmed by acLDL uptake and BS-1 lectin reactivity (Figure 8), 
were lower in the peripheral blood of diabetic mice than in control non-diabetic mice.  
 
6. Impaired ischemia-induced neovascularization in the diabetic mice 
Because of the aforementioned bone marrow-derived EPCs and MSCs dysfunction and de novo 
defect of skeletal muscle such as the reduced VEGF-A, we hypothesized that neovascularization 
after hindlimb ischemia surgery would be hampered in the diabetic mice. To figure out this 
hypothesis, left hindlimb ischemia surgery was conducted. All mice survived after surgical 
induction of left hindlimb ischemia. Figure 9A showed the representative LDPI images of 
hindlimb blood flow before surgery, immediately after surgery, and at 28 days after surgery in 
the diabetic and non-diabetic mice. Immediately after left femoral artery and vein resection, the 
ratio of blood flow between the ischemic and non-ischemic hindlimb decreased to 0.11±0.006 
and 0.12±0.008 in the diabetic mice and non-diabetic mice, respectively, indicating that the 
severity of the induced ischemia was comparable in the 2 experimental groups. In the normal 
non-diabetic C57BL/6 mice, hindlimb blood flow perfusion recovered to 84% 
(ratio=0.84±0.006) of the non-ischemic limb by the day 28 (Figure 9). In contrast, flow 
recovery in the diabetic mice was impaired, and the deficits in flow were statistically significant 
at 14, 21, 28 days after surgery  
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Figure 8. Circulating EPCs culture assay. EPCs were characterized as adherent cells with 
double-positive staining for AcLDL-Dil and BS-1 lectin. A: Representative 
immunofluorescence image with positive AcLDL-Dil and BS-1 lectin showed double positive 
spindle-shaped attaching cells. B: Quantification of cells in normal non-diabetic and diabetic 
mice. The number of the circulating EPCs in the diabetic nice was much less than that of the 
normal non-diabetic mice. Values are means± SEM, n= 5 per group (P<0.05).  
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Figure 9. Laser Doppler flow image. A. Ischemia-induced changes in hindlimb blood flow 
monitored in vivo by laser Doppler perfusion imaging performed for a month weekly after 
ischemia in diabetic and non-diabetic mice. In color coded images, normal blood flow is 
depicted in red. A marked reduction in blood flow of ischemic hindlimb is depicted in blue. The 
figure a, b shows the pre and post image from the non-diabetic mice at day 0. The figure c, d 
shows pre and post image from the diabetic mice at day 0. The figure e, f shows LDPI from 
non-diabetic and diabetic at day 28, respectively. At day 0, pre- and post-image reveals 
significant blood flow reduction immediately after surgery. However, at day 28, normal non-
diabetic mice recovered almost the same color scale (e) but still bluish in the diabetic mice 
(f). B: Quantitative evaluation of blood flow expressed as a ratio of blood flow in 
ischemic foot to that in non-ischemic one. Values are means ± SEM, n= 7 per group. 
*P <0.05.  
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7. Therapeutic effect of bone marrow-derived EPCs or MSCs 
Blood flow of the ischemic hindlimb was measured by a non-invasive method using a laser 
Doppler perfusion imaging system. After hindlimb ischemia with stem cell transplantation for a 
month weekly, we found that the blood flow of the ischemic hindlimb in the diabetic mice was 
remarkably better in the EPCs or MSCs injected group than in the saline group (Fig. 10). 
However, there was no significant difference between EPCs and MSCs transplantation.  
 
8. Mechanisms mediating therapeutic effects 
A. Histopathology with capillary density 
To evaluate the extent of vascular remodeling at the level of the microcirculation in diabetic and 
non-diabetic mice after stem cell treatment, quantitative analysis of capillary density in 
ischemic adductor muscle of diabetic and non-diabetic C57BL/6 mice was determined in 
histological sections harvested on the postoperative day 14. Quantitative analysis of CD31-
positive cells revealed that the capillary density in the ischemic limb was essentially increased 
in the EPCs or MSCs treated diabetic mice (Figure 11) compared to the saline injected mice, 
indicative of an improved angiogenic response with the stem cell transplantation in these 
animals. However, there was no significant difference between EPCs or MSCs in the capillary 
density.  
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Figure 10. Ischemia-induced changes in hindlimb blood flow monitored in vivo by laser 
Doppler perfusion imaging performed for a month weekly after ischemia in diabetic and non-
diabetic mice treated with endothelial progenitor cells (EPCs) and mesenchymal stem cells 
(MSCs) isolated from non-diabetic normal mice. A: Quantitative evaluation of blood flow 
expressed as a ratio of blood flow in ischemic foot to that in non-ischemic one. Values are 
means± SEM, n =7 per group. *P< 0.05 DM saline versus EPCs-injected diabetic animals. , # P 
< 0.05 DM saline versus MSCs injected diabetic animals.  B: In color coded images, normal 
blood flow is depicted in red. A marked improvement of blood flow at 28 days of ischemic 
hindlimb in the EPCs or MSCs treated groups compared to saline injected group.  
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Figure 11. Capillary density of hindlimb muscle with CD31 immunofluorescence staining after 
stem cell transplantation. A: Representative pictures from saline (a), endothelial progenitor cells 
(EPCs) (b), and mesenchymal stem cell (MSCs) (c) transplantation to diabetic hindlimb 
ischemia.  B: Quantitative analysis showed that the number of capillary was significantly 
higher in the EPCs or MSCs treated diabetic hindlimb compare to the saline injected groups. 
However, there was no significant difference between EPCs and MSCs treated groups.  
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Figure 12. In vivo Fluorescein griffonia simplicifolia lectin I perfusion staining of hindlimb 2 
weeks after hindlimb ischemia and cell treatment showed that cell were still alive and some of 
them are co-localized with lectin stained capillary (green : lectin I, red : AcDiI labeled EPC(a), 
MSC(b), blue : DAPI).  
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B. Cell fate or engraftment potential determination 
To find out the survival of injected stem cells, the cells were stained with red fluorescence diI. 
Two weeks after cell transplantation, there are numerous injected stem cells in the hindlimb 
muscle which was seen as a red color in the fluorescence microscopy (Figure 12).  
 
C. Transdifferentiation potential: co-localization with vessels 
To tract the injected cells spatial placement with vessels in the tissue, we injected green 
fluorescence isolectin B4 intravenously to stain vessels in vivo immediately before the sacrifice 
two weeks after hindlimb surgery and cell transplantation. On the immunofluorescence 
microscopy, some of the injected red colored cells are co-localized with the green vessels which 
mean close proximity of stem cells in to vessels or possible transdifferentiation in to capillary 
(Figure 12). 
 
D. Proliferation effect in vivo in hindlimb tissue 
To compare the quantitative effect of stem cell’s proliferation effect of other cells, we stained 
the hindlimb muscle with Ki67. It revealed higher proliferating cell numbers in the cell treated 
groups (EPCs, MSCs) compared to the saline injected group (Figure 13).  
 
E. mRNA expression of various angiogenic factors or other cytokines related with cell  
survival, mobilization of bone marrow-derived stem cells 
Two weeks after cell transplantation, to observe the changes of mRNA amount of the various 
angiogenic factors, mice were sacrificed and real time RT-PCR with the skeletal muscle was 
performed.  We measured the mRNA amount of VEGF-A, fibroblast growth factor-2 (FGF-2), 
hypoxia inducible factor-1α (HIF-1α), platelet derived growth factor (PDGF), placenta growth 
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factor (PlGF), hepatocyte growth factor (HGF), angiopoietin-1, angiopoietin-2, and stromal 
derived factor (SDF) with the 2 weeks old hind limb tissues. The amount of mRNA of VEGF-A, 
HIF-1α, and FGF-2 were significantly higher in the EPC-treated hindlimb tissue compared to 
saline injected group. The mRNA of the cytokines of the MSCs treated group was not 
significantly higher compared to the saline treated group (Table 4).  
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Figure 13. Ki67 immunofluorescence showed higher number of proliferating cells (arrow) in the 
endothelial progenitor cells (EPCs) and mesenchymal stem cells (MSCs) treated group 
compared to saline treated group. There was no significant difference between EPCs and MSCs 
group (red: Ki67, blue: DAPI).  
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Table 7. Real time RT-PCR data of various cytokines from diabetic hindlimb after stem cell 
transplantation. 
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IV. DISCUSSION  
Diabetic mice showed different pathophysiological findings compared to the normal in their 
features of neovascularization, stem cell functions, and response to the ischemia. We firstly 
assumed that diabetes has decreased neovascularization in the hindlimb muscle in not only with 
the ischemia injury but also in absence of ischemic injury. We compared the basal level of 
capillaries in the diabetic and normal mice and found that diabetic mice had the fewer number 
of capillary. The blood flow recovery measured with laser Doppler after ischemia showed 
impaired response. This is very true when we see the human cases. Diabetes patients have the 
delayed wound healing process. This is probably related the decreased the vascularity in the 
diabetic condition. When we count the capillary density in the diabetic hindlimb, we found the 
unusual findings in terms of counting of capillary in the microscopy because of the 
morphological change of diabetic skeletal muscle.  As showed in the figure 1, there was 
atrophy of skeletal muscle. Therefore, if one counts the total number of capillary in the high 
power field such as 400 magnifications routinely, it would reveal the increased capillary number. 
Hence, in this case, capillary density per single myofiber should be counted. Figure 2 showed 
that the number of capillary per single myofiber is fewer in the diabetic muscle compare to 
normal. These findings were observed in other papers. Computer-assisted morphometric 
analysis of myofiber size by fiber type indicated a significant difference in myofiber size for the 
type 2b fibers in muscles from diabetic mice. Similarly, there was a shift in the fiber size 
distribution to include a greater number of small type 2a, 2b myofibers when compared to 
controls. Skeletal muscle from diabetic mice exhibited a significant change in the percentage of 
fiber types, with an increase in the number of type 2a fibers, a fiber type grouping38. In another 
report, morphometric analysis revealed that muscle fiber cross-sectional area was reduced 39% 
in diabetic rats, which, despite a lower capillary-to-fiber ratio, resulted in a 27% increase in 
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capillary density in diabetic rats39. This finding was observed in our experiment as showed in 
figure 2. Therefore, it is quite sure that capillary density should count not on a whole section but 
on a single myofiber when used as a therapeutic indicator in the diabetic mice.  
To reveal the reasons of the decreased neovascularization in the diabetes, we performed various 
kinds of experiments. When we compared the VEGF-A mRNA content from the hindlimb, it 
was significantly lower in the skeletal muscle of the diabetic mice. These findings were also 
observed in the previous study with human40 and mouse skeletal muscle 32. It revealed that when 
vascular injury occurs in the limbs, the recovery potential might be limited.   
As a consequence of defectiveness of the skeletal muscle itself, they need some important 
helpers. We also hypothesized that the decreased neovascularization probably related some 
defect of the bone marrow stem cells. One of them is the circulating EPCs. As we expected, the 
number of circulating EPCs was much less in the diabetic mice as showed in these experiments. 
These have been reported in human study27, 41. Therefore, they need other supporters. It has been 
quite true that the bone marrow derived stem cells are recruited into injury site and participate 
the reparative process15-18.  
However, as our data showed, diabetic bone marrow derived stem cells has the defect of 
paracrine function, cell adhesion, and cell migration, as well as tube formation.  The 
Microarray data showed that a total of 12 cytokines from112 tested genes including Akt-1, Npr1, 
Nrb1, and TGFb-3 were less in the diabetic BM-MNCs compared to those of normal (Table 3). 
These findings were also observed with EPCs, MSCs Microarray data. Diabetic EPCs had a 
total of 11 cytokines reduced such as PDGFb, TFGb3 (Table 4). Diabetic MSCs showed 
reduced Akt1, PDGFa (Table 5). These results were also confirmed with real time RT-PCR. 
Bone marrow derived MNCs of diabetic mice have less amount of mRNA of significant 
angiogenic cytokines such as, angiopietin-1, and VEGF-A, IGF-1 compared to the normal cells 
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as the results showed above on the figure 4. EPCs and MSCs cultured from the bone marrow-
derived MNCs also had the lower level of VEGF-A compared to the normal cells (figure 5).   
When it comes to say paracrine effect, which means the stem cells secrete some important 
cytokines into the local tissue after homing to the needed area, decreased content of the genes or 
mRNA of the important cytokines related to angiogenesis might have resulted in the abnormal 
paracrine function, Therefore, it is convinced that the role of bone marrow in the regenerative 
process are defective in the diabetic mice.  
Furthermore, in terms of bone marrow derived stem cell function, adhesion assay of EPCs to 
vitronectin and lamine showed decreased attached cell number in the diabetic stem cells 
compared to the normal stem cells (Table 6). These findings were also observed in the other 
paper with some different findings 19.  They described that EPCs adhesion to Fibronectin, 
collagen was not reduced but reduced in the adhesion to human umbilical vein endothelial cells 
activated by tumor necrosis factor-alpha (TNF-alpha). The tube formation assay of EPCs also 
showed much less organized tube in the diabetic cells (figure 6). Usually in the tube formation 
assay one count the number of the attached stem cells such as EPCs to the human umbilical vein 
endothelia cells (HUVEC). However, we only cultured EPCs in Matrigel for 4 days without 
HUVEC and observed distinct tube morphology from normal EPCs. When MSCs were exposed 
to Matrigel to form the tube, they did not make tube morphology. The migration assay of the 
EPCs to the VEGF-A showed the similar result from other reports that diabetic cells are less 
migrated than normal cells. In these experiments, we firstly did the migration assay with 
diabetic MSCs and showed decreased migration ability of the diabetic MSCs. From all these 
functional assays, we can assume that, when injury occurs to the diabetic mice, the ability of 
homing of the bone marrow derived stem cell to the injury sites and participation to the 
regeneration would be hampered.  
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The reasons why diabetic stem cells have a various functional impairment were proposed from 
some researchers as below.  Adverse metabolic factors, including oxidized small and dense low 
density lipoprotein (ox-dmLDL) can contribute to the reduced number and the impaired 
functions of EPCs in diabetic patients42. Increased oxidative stress could play a role in the 
development of EPC dysfunction in type 1 DM43.  
To improve the regeneration capability in the diabetes, we hypothesized that normal non-
diabetic stem cell transplantation could be the way out of this whole scenario. Therefore, we 
treated bone marrow derived EPCs and MSCs collected from the normal mice in to the diabetic 
mice hindlimb injury site. There have been some reports about EPCs or MSCs cell treatment in 
to non-diabetic hindlimb injury models. However, there are only one report of EPCs treatment 
for the diabetic hindlimb ischemia26 and no data with MSCs so far.  Two weeks after cell 
treatment, the laser Doppler blood flow showed the significantly better results compared to the 
saline injected groups even though they did not show the same good findings as showed in the 
normal mice recovery process after ischemia.  The therapeutic effect of EPCs and MSCs were 
comparable.  
To delineate the mechanism of this favorable therapeutic effect of the normal stem cell 
treatment to the diabetic hindlimb ischemia, we did several experiments. Firstly, we observed 
the pathology, if they increased the capillary density in the diabetic hindlimb muscle after 
ischemia and cell transplantation. The number of capillary density of cell treated groups showed 
higher than saline injected group. We proposed that the mechanism of this improved recovery 
and capillary density is probably from the paracrine effect of the normal injected stem cells. 
This is because the diabetic cells had decreased amount of important angiogenic cytokines as 
documented in this experiments. The normal stem cells can overcome these flaws and contribute 
fully in the regeneration when injected into the ischemic sites.  Our hypothesis was 
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documented by increased mRNA amount of VEGF-A, HIF-1a, FGF-2, PlGF in the hind limb 
tissue after cell therapy compared to the saline injected group. The other positive effect of stem 
cell treatment was the increased cell proliferation number as showed on the result. Furthermore, 
the injected EPCs and MSCs were still alive in the mice until 2 weeks after treatment and also 
there were some co-localized stem cells with the capillary of the hindlimb muscle which suggest 
of the possibility of the transdifferentiation of the injected stem cell in to one of the structures of 
vessels. 
In the comparison of stem cell’s therapeutic effects, there is one data that compared BM-MNC 
and MSCs17. They reported that MSCs are better that BM-MNC in terms of capillary density 
and laser Doppler blood flow. In our study, we compared the characteristics and therapeutic 
effect of the EPCs and MSCs. In the Microarray data, we found that diabetic EPCs had 12 
cytokines reduced compared to normal EPCs, but diabetic MSCs showed 3 cytokines that 
reduced compared normal MSCs. We assumed that it probably related the different 
characteristics between EPCs and MSCs as well as the recovery of the cell function during cell 
culture in the case of MSCs. The therapeutic effect observed by capillary density and laser 
Doppler blood flow after transplantation did not show difference between MSCs and EPCs. 
We concluded that diabetes mellitus is the condition of impaired neovascularization and this is 
berceuse of the decrease the angiogenic cytokines in the hindlimb itself and reduced number and 
function of the bone marrow derived EPCs or MSCs in the process of regeneration process.  
The normal bone marrow-derived stem cells may overcome these defects when transplanted in 
to the diabetic hindlimb ischemia. These findings can be applied to the clinical field of 
peripheral artery disease in the diabetes mellitus.  
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V. CONCLUSION  
Diabetes mellitus has the impaired angiogenic process after hindlimb ischemia. It might be from 
the change of the skeletal muscle characteristics and dysfunction of the circulating and bone 
marrow derived stem cells. However, normal bone marrow derived stem cells transplantation 
showed the favorable effects in the recovery of diabetic hindlimb ischemia.   
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Abstract (In Korean)  
 
당뇨병성 하지 혈관 질환 모델에서의 골수 줄기 세포 치료 
 
<지도교수 정 남식>  
 
연세대학교 대학원 의학과  
 
이 주 용  
 
당뇨병은 심장 혈관 질환의 가장 중요한 위험 요소 중에 하나이며 최근 그 
유병율과 발병율이 증가하여 중요한 보건학적 사회문제로 부각되고 있다. 당뇨병 
환자에서 상처 회복이 느리고 조직 손상 시 회복이 느린 것은 경험적으로 알려져 
있다. 본 연구의 목적은 쥐를 이용하여 당뇨병에서 하지 허혈 시 재생이 느린 
이유를 밝히고 혈관 전구세포나 간엽 줄기 세포와 같은 골수에서 유래한 줄기 
세포의 기능을 평가하며 골수 줄기세포를 당뇨병이 유발된 쥐의 급성 하지 허혈 
모델에 사용 했을 때의 치료 효과를 보기 위함이다.  
당뇨병에서 하지 혈관 손상 후 정상으로 회복이 지연되는 것은 골격근 내에 
VEGF-A 가 적고, 말초 혈액 내에 있는 혈관 전구세포의 수가 적으며 골수에서 
유래하는 혈관 전구세포 그리고 간엽 줄기 세포의 혈관 재생에 관여하는 세포 
기능이 떨어진 것 때문인 것으로 사료된다.  또한 당뇨병 쥐에서 얻은 골수 유래 
전구세포는 VEGF-A 등의 중요한 혈관 재생에 필요한 cytokine 의 mRNA 양이 
정상 쥐에서 얻은 세포에 비해 적었다. 정상 쥐에서 채취한 혈관 전구 세포와 간엽 
줄기 세포를 당뇨병 쥐의 하지 허혈 수술 후 주사 한 결과 대조군에 비해 현저한 
혈류 개선 효과를 보여 주었다. 주사한 세포는 2 주 관찰 하는 동안 조직 내에서 
살아 있었으며 골격근 내에서 미세 혈관 및 증식 중인 세포의 개수가 증가된 것을 
보여주었다. 이는 투여한 세포에서 분비되는 VEGF-A, FGF-2, PlGF 등의 혈관 
조성에 관여하는 단백질의 증가 효과와 줄기 세포가 미세 혈관을 구성하는 일부 
세포로 분화되었기 때문으로 본 연구 결과 추론할 수 있었다.  
결론적으로 당뇨병에서 하지 허혈에 대한 회복이 느린 것은 당뇨병에 의한 하지 
조직 자체의 변화와 골수 및 말초 혈액에서 줄기 세포의 기능이 떨어진 것에 
기인한 것으로 사료되며 정상 골수 줄기 세포를 이용하면 허혈 손상 시 치료 
효과를 얻을 수 있을 것으로 사료 된다.  
------------------------------------------------------------- 
핵심 되는 말 : 당뇨병, 줄기 세포, 하지 허혈, 혈관전구 세포, 골수 간엽 줄기 세포  
